We are live on ! Find out more
TRVI icon

Trevi Therapeutics
TRVI

40 hedge funds and large institutions have $70.5M invested in Trevi Therapeutics in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

40% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 10

25% more funds holding

Funds holding: 32 → 40 (+8)

4.17% more ownership

Funds ownership: 74.31% → 78.48% (+4.2%)

11% less capital invested

Capital invested by funds: $79.6M → $70.5M (-$9.13M)

Holders
40
Holders Change
+8
Holders Change %
+25%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
14
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
+$14.4M
2
FLSM
Frazier Life Sciences Management
California
+$13.9M
3
FFM
Fairmount Funds Management
Pennsylvania
+$13.4M
4
RCMNY
Rubric Capital Management (New York)
New York
+$12.8M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.84M

Top Sellers

Rank Fund Capital Flow
1
TGA
TPG GP A
Texas
-$13.4M
2
EI
EAM Investors
California
-$1.03M
3
ACM
Altium Capital Management
New York
-$714K
4
JGC
J. Goldman & Co
New York
-$150K
5
Millennium Management
Millennium Management
New York
-$86K
Name Holding Trade Value Shares
Change 		Change in
Stake
JF
26
Jump Financial
Illinois
$66K +$141K +42,977 New
Millennium Management
27
Millennium Management
New York
$62K -$86K -26,222 -40%
Northern Trust
28
Northern Trust
Illinois
$61K -$20.9K -6,371 -14%
ACP
29
Acuta Capital Partners
California
$56K +$4.27K +1,302 +4%
UBV
30
United Bank (Virginia)
Virginia
$44K – – –
LPL Financial
31
LPL Financial
California
$31K +$32.8K +10,000 +100%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$22K +$46.2K +14,098 New
Charles Schwab
33
Charles Schwab
California
$20K – – –
CS
34
Credit Suisse
Switzerland
$16K +$34K +10,374 New
TRCT
35
Tower Research Capital (TRC)
New York
$15K +$19.4K +5,912 +153%
UBS Group
36
UBS Group
Switzerland
$7K -$1.62K -494 -10%
First Manhattan
37
First Manhattan
New York
$2K -$3.28K -1,000 -40%
Federated Hermes
38
Federated Hermes
Pennsylvania
$1K +$2.86K +872 New
FIA
39
FNY Investment Advisers
New York
– -$22K -7,986 Closed
Citigroup
40
Citigroup
New York
– -$5K -1,700 Closed
CWM
41
Curi Wealth Management
North Carolina
– -$3K -998 Closed
Wells Fargo
42
Wells Fargo
California
– -$89 -27 -16%
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
– +$489 +149 New
1
2

TRVI Hedge Fund Activity: Q3 2022 in Review

40 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2022, worth a combined $70.5M — down 11% from $79.6M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new TRVI positions and 3 closed out — a net gain of 8 holders — while 14 added to existing stakes and 10 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $14.4M. The largest seller was TPG GP A, cutting an estimated $13.4M.

  • 40 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2022, up from 32 in Q2 2022.
  • Funds reported $70.5M of Trevi Therapeutics stock for Q3 2022, down 11% quarter-over-quarter.
  • 11 funds opened new Trevi Therapeutics positions in Q3 2022 and 3 closed out, a net change of +8 holders.
  • The largest Trevi Therapeutics buyer in Q3 2022 was Viking Global Investors, an estimated $14.4M added.
  • The largest Trevi Therapeutics seller in Q3 2022 was TPG GP A, an estimated $13.4M sold.

Based on aggregated 13F filings for Q3 2022.